Kamada (KMDA) Operating Leases (2018 - 2026)
Kamada's (KMDA) quarterly Operating Leases came in at $9.5 million in Q2 2026, little changed on a YoY basis from $9.5 million in Q2 2025, and up 0.76% quarter-over-quarter from $9.4 million in Q1 2026.
Analysis
Kamada (KMDA) Operating Leases (2018 - 2026) Analysis & Trends
Kamada (KMDA) has reported Operating Leases for 9 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Leases changed 0.36% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $9.5 million (changed 0.36% YoY), and the FY2025 full-year result was $9.4 million, changed 0.1% from the prior year.
- Operating Leases rose to $9.5 million in Q2 2026 per KMDA's latest filing, from $9.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $9.6 million in Q3 2024 and bottomed at $2.2 million in Q4 2022.
- Historically, Operating Leases has averaged $6.8 million across 5 years, with a median of $7.4 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 31.11% in 2022, then jumped 241.66% in 2023.
- Over 5 years, Operating Leases stood at $2.2 million in 2022, then surged by 241.66% to $7.4 million in 2023, then climbed by 26.79% to $9.4 million in 2024, then advanced by 0.1% to $9.4 million in 2025, then rose by 0.79% to $9.5 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $9.5 million, $9.4 million, and $9.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.52 Mn |
| Mar 31, 2026 | 9.44 Mn |
| Dec 31, 2025 | 9.44 Mn |
| Sep 30, 2025 | 9.56 Mn |
| Jun 30, 2025 | 9.55 Mn |
| Mar 31, 2025 | 9.32 Mn |
| Dec 31, 2024 | 9.43 Mn |
| Sep 30, 2024 | 9.57 Mn |
| Jun 30, 2024 | 7.07 Mn |
| Mar 31, 2024 | 7.28 Mn |
| Dec 31, 2023 | 7.44 Mn |
| Sep 30, 2023 | 4.72 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 4.99 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 2.41 Mn |
| Jun 30, 2022 | 2.49 Mn |
| Mar 31, 2022 | 3.06 Mn |
| Dec 31, 2021 | 3.16 Mn |
| Sep 30, 2021 | 3.28 Mn |